Is DocuSign Stock Undervalued?
Digital signature software business DocuSign (NASDAQ:DOCU) has been struggling over…
Buy
70
CRDF Quote, Financials, Valuation and Earnings
Last price:
$3.18
Seasonality move
:
11.94%
Day range:
$2.88 - $3.24
52-week range:
$1.90 - $4.99
Dividend yield:
0%
P/E ratio:
--
P/S ratio:
404.91x
P/B ratio:
4.39x
Volume:
1.4M
Avg. volume:
980.2K
1-year change:
-18.88%
Market cap:
$214.2M
Revenue:
$683K
EPS (TTM):
-$0.79
Analysts' Opinion
-
Consensus RatingCardiff Oncology, Inc. has received a consensus rating of Buy. The company's average rating is a Buy based on 6 Buy ratings, 1 Hold rating, and 0 Sell ratings.
-
Price Target UpsideAccording to analysts' consensus price target of $9.75, Cardiff Oncology, Inc. has an estimated upside of 206.6% from its current price of $3.18.
-
Price Target DownsideAccording to analysts, the lowest downside price target is $2.50 representing 100% downside risk from its current price of $3.18.
Fair Value
-
According to the consensus of 7 analysts, Cardiff Oncology, Inc. has 206.6% upside to fair value with a price target of $9.75 per share.
CRDF vs. S&P 500
-
Over the past 5 trading days, Cardiff Oncology, Inc. has overperformed the S&P 500 by 30.09% suggesting its relative strength compared to the major market average is strong at this time.
Share Buyback
-
Cardiff Oncology, Inc. does have a share repurchase program in place at this time. The scale of a buyback program can materially affect share price and usually results in a higher earnings per share, all else being equal, when the share count drops.
Revenue Growth
-
Cardiff Oncology, Inc. revenues have been falling on a year-over-year basis for 4 quarters in a row. In the most recent quarter Cardiff Oncology, Inc. reported revenues of $120K.
Earnings Growth
-
Cardiff Oncology, Inc. has grown year-over-year earnings for 3 quarters straight. In the most recent quarter Cardiff Oncology, Inc. reported earnings per share of -$0.17.
Enterprise value:
154.6M
EV / Invested capital:
3.10x
Price / LTM sales:
404.91x
EV / EBIT:
--
EV / Revenue:
308.63x
PEG ratio (5yr expected):
-1.62x
EV / Free cash flow:
-3.66x
Price / Operating cash flow:
--
Enterprise value / EBITDA:
--
Gross Profit (TTM):
-$276K
Return On Assets:
-65.58%
Net Income Margin (TTM):
-10064.27%
Return On Equity:
-81.17%
Return On Invested Capital:
-79.44%
Operating Margin:
-9978.33%
| Trailing 12 Months | Fiscal Quarters | |||||
|---|---|---|---|---|---|---|
| Period Ending | 2023-09-30 | 2024-09-30 | 2025-09-30 | 2024-09-30 | 2025-09-30 | |
| Income Statement | ||||||
| Revenue | $460K | $689K | $501K | $165K | $120K | |
| Gross Profit | $115K | $278K | -$276K | $64K | -$104K | |
| Operating Income | -$44.5M | -$46.4M | -$53.7M | -$12.6M | -$12M | |
| EBITDA | -$44.1M | -$46M | -$52.9M | -$12.5M | -$11.8M | |
| Diluted EPS | -$0.91 | -$0.95 | -$0.79 | -$0.25 | -$0.17 | |
| Period Ending | 2021-09-30 | 2022-09-30 | 2023-09-30 | 2024-09-30 | 2025-09-30 | |
|---|---|---|---|---|---|---|
| Balance Sheet | ||||||
| Current Assets | $137.8M | $119.8M | $83.9M | $59.3M | $61.8M | |
| Total Assets | $141.3M | $123.6M | $88.5M | $62.9M | $63.8M | |
| Current Liabilities | $5M | $8.2M | $9M | $12.5M | $14.7M | |
| Total Liabilities | $7.8M | $10.4M | $10.6M | $13.5M | $15M | |
| Total Equity | $133.5M | $113.2M | $77.8M | $49.4M | $48.8M | |
| Total Debt | $3.3M | $2.2M | $1.6M | $979K | $284K | |
| Trailing 12 Months | Fiscal Quarters | |||||
|---|---|---|---|---|---|---|
| Period Ending | 2023-09-30 | 2024-09-30 | 2025-09-30 | 2024-09-30 | 2025-09-30 | |
| Cash Flow Statement | ||||||
| Cash Flow Operations | -$33.1M | -$34.6M | -$42.2M | -$10.5M | -$10.8M | |
| Cash From Investing | $29.7M | $22.8M | -$4.9M | -$9.4M | $10.2M | |
| Cash From Financing | -- | $9.6M | $44.2M | $7.4M | $25K | |
| Free Cash Flow | -$33.8M | -$34.7M | -$42.3M | -$10.5M | -$10.9M | |
CRDF
Sector
Market Cap
$214.2M
$28.1M
Price % of 52-Week High
63.73%
51.39%
Dividend Yield
0%
0%
Shareholder Yield
-31.87%
-1.49%
1-Year Price Total Return
-18.88%
-17.13%
Beta (5-Year)
1.351
0.518
Dividend yield:
0%
Annualized payout:
$0.00
Payout ratio:
--
Growth streak:
0 years
Technicals
8-day SMA
Buy
Level
$2.60
200-day SMA
Buy
Level
$2.78
Bollinger Bands (100)
Buy
Level
2.05 - 2.43
Chaikin Money Flow
Sell
Level
-8.7M
20-day SMA
Buy
Level
$2.39
Relative Strength Index (RSI14)
Buy
Level
80.38
ADX Line
Buy
Level
26.11
Williams %R
Sell
Level
-5.2174
50-day SMA
Buy
Level
$2.28
MACD (12, 26)
Buy
Level
0.17
25-day Aroon Oscillator
Buy
Level
88
On Balance Volume
Sell
Level
-17.6M
Financial Scores
Buy
Altman Z-Score
(Annual)
Level (5.9931)
Sell
CA Score
(Annual)
Level (-1.2913)
Buy
Beneish M-Score
(Annual)
Level (-2.3068)
Buy
Momentum Score
Level (3)
Sell
Ohlson Score
Level (5.2341)
Buy
Piotroski F Score
(Annual)
Level (5)
Sell
Quality Ratio Score
Level (1)
Buy
Fundamental Score
Level (3)
Revenue Forecast
Earnings per Share Forecast
Company Profile
Cardiff Oncology, Inc. is an oncology therapeutics company, which engages in the development of drugs that target mitosis for the treatment of various types of cancer. It is focused on developing onvansertib, a first-in-class, third-generation Polo-like Kinase 1 (PLK1) inhibitor, in combination with standard-of-care chemotherapy and targeted therapeutics. The firm's clinical programs include KRAS-Mutated Metastatic Colorectal Cancer (mCRC), Resistant Metastatic Castration-Resistant Prostate Cancer (mCRPC) and relapsed or refractory Acute Myeloid Leukemia (AML). The company was founded by Gabriel M. Cerrone, L. David Tomei, Samuil Umansky, and Hovsep Melkonyan in 1999 and is headquartered in San Diego, CA.
Stock Forecast FAQ
In the current month, CRDF has received 6 Buy ratings 1 Hold ratings, and 0 Sell ratings. The CRDF average analyst price target in the past 3 months is $9.75.
-
Where Will Cardiff Oncology, Inc. Stock Be In 1 Year?
According to analysts, the consensus estimate is that Cardiff Oncology, Inc. share price will rise to $9.75 per share over the next 12 months.
-
What Do Analysts Say About Cardiff Oncology, Inc.?
Analysts are divided on their view about Cardiff Oncology, Inc. share price and where it will be in the next 12 months. The majority of analysts rate the stock a Buy. However, a smaller subset of analysts suggest that Cardiff Oncology, Inc. is a Sell and believe this share price will drop from its current level to $2.50.
-
What Is Cardiff Oncology, Inc.'s Price Target?
The price target for Cardiff Oncology, Inc. over the next 1-year time period is forecast to be $9.75 according to 7 Wall Street analysts, 6 of them rate the stock a Buy, 0 rate the stock a Sell, and 1 analyst rates the stock a Hold.
-
Is CRDF A Buy, Sell Or Hold?
According to Wall Street analysts, the consensus rating for Cardiff Oncology, Inc. is a Buy. 6 of 7 analysts rate the stock a Buy at this time.
-
How Can I Buy Shares Of CRDF?
You can purchase shares of Cardiff Oncology, Inc. via an online brokerage firm such as TD Ameritrade.com, thinkorswim.com, e-trade.com, or Schwab.com. Many other digital online brokerages exist such as RobinHood and Webull where you can purchase Cardiff Oncology, Inc. shares.
-
What Is The Cardiff Oncology, Inc. Share Price Today?
Cardiff Oncology, Inc. was last trading at $3.18 per share. This represents the most recent stock quote for Cardiff Oncology, Inc.. Yesterday, Cardiff Oncology, Inc. closed at $3.18 per share.
-
How To Buy Cardiff Oncology, Inc. Stock Online?
In order to purchase Cardiff Oncology, Inc. stock online, open a brokerage account, deposit funds into the account, and select an order type to purchase shares whether it be market or limit.
Get CRDF Stock Alert
Signup to receive the latest stock alerts
Financial Ratios
CRDF
Sector
P/E ratio
--
23.89x
PEG ratio
-1.62x
-0.01x
P/B ratio
4.39x
1.81x
Price / LTM sales
404.91x
1.59x
Growth Metrics
CRDF
Sector
Revenue growth
-27.27%
4.62%
Earnings growth
33.47%
11.06%
Revenue (5-year growth)
22.8%
6.5%
Earnings forecast
-$0.21
-$0.21
Profitability
CRDF
Sector
Profitability FY 2024
$279K
$3.6M
Return on invested capital
-79.44%
-31.84%
Return on assets
-65.58%
-27.96%
Return on equity
-81.17%
-37.63%
Earnings Date
Last Earnings Date
Nov
6
Next Earnings Date
Feb
26
Estimated Next Earnings Date
Feb
5
Balance Sheet
CRDF
Sector
Total cash
$60.6M
$26.4M
Short term investments
$40.3M
$25.7M
Total assets
$97.2M
$76.9M
Long term debt
$284K
$3.3M
SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS
GET BETTER TRADE IDEAS
Popular
Is SentinelOne Stock Undervalued?
Cybersecurity major SentinelOne (NYSE:S) has struggled over several years, delivering…
Is Broadcom Stock on Sale?
Chip and software maker Broadcom (NASDAQ:AVGO) has been among the…
Stock Ideas
Buy
57
Is NVDA Stock a Buy?
Market Cap: $4.6T
P/E Ratio: 64x
Buy
55
Is AAPL Stock a Buy?
Market Cap: $4T
P/E Ratio: 37x
Buy
61
Is GOOG Stock a Buy?
Market Cap: $3.8T
P/E Ratio: 39x
Alerts
Buy
87
HUT alert for Dec 25
Hut 8 Corp. [HUT] is up 0.65% over the past day.
Buy
80
TVTX alert for Dec 25
Travere Therapeutics, Inc. [TVTX] is up 14.03% over the past day.
Buy
60
GPCR alert for Dec 25
Structure Therapeutics, Inc. [GPCR] is down 2.36% over the past day.
THE #1 STOCK ANALYSIS TOOL
TO MAKE SMARTER BUY AND SELL DECISIONS
Show me the best stock
